BR9810779A - Processos para inibir a reabsorção óssea em um mamìfero, para tratar e prevenir a osteoporose em um mamìfero, para tratar e prevenir a reabsorção óssea anormal em um ser humano, composição farmacêutica, e, conjunto para inibir a reabsorção óssea em um mamìfero - Google Patents
Processos para inibir a reabsorção óssea em um mamìfero, para tratar e prevenir a osteoporose em um mamìfero, para tratar e prevenir a reabsorção óssea anormal em um ser humano, composição farmacêutica, e, conjunto para inibir a reabsorção óssea em um mamìferoInfo
- Publication number
- BR9810779A BR9810779A BR9810779-8A BR9810779A BR9810779A BR 9810779 A BR9810779 A BR 9810779A BR 9810779 A BR9810779 A BR 9810779A BR 9810779 A BR9810779 A BR 9810779A
- Authority
- BR
- Brazil
- Prior art keywords
- mammal
- bone resorption
- treat
- processes
- inhibit bone
- Prior art date
Links
- 208000006386 Bone Resorption Diseases 0.000 title abstract 4
- 241000124008 Mammalia Species 0.000 title abstract 4
- 230000024279 bone resorption Effects 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 208000001132 Osteoporosis Diseases 0.000 title abstract 2
- 230000002159 abnormal effect Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 210000000988 bone and bone Anatomy 0.000 abstract 2
- 230000009103 reabsorption Effects 0.000 abstract 2
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 abstract 1
- 229940122361 Bisphosphonate Drugs 0.000 abstract 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 abstract 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 abstract 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 abstract 1
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 229940062527 alendronate Drugs 0.000 abstract 1
- 230000000712 assembly Effects 0.000 abstract 1
- 238000000429 assembly Methods 0.000 abstract 1
- 150000004663 bisphosphonates Chemical class 0.000 abstract 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 abstract 1
- 229960002286 clodronic acid Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 229940009626 etidronate Drugs 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 abstract 1
- 229940015872 ibandronate Drugs 0.000 abstract 1
- LWRDQHOZTAOILO-UHFFFAOYSA-N incadronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 abstract 1
- 229950006971 incadronic acid Drugs 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 abstract 1
- 229940046231 pamidronate Drugs 0.000 abstract 1
- -1 pyrhydronate Chemical compound 0.000 abstract 1
- 229940089617 risedronate Drugs 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 229940019375 tiludronate Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compounds Of Unknown Constitution (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
- Saccharide Compounds (AREA)
- Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
- Pit Excavations, Shoring, Fill Or Stabilisation Of Slopes (AREA)
- Aiming, Guidance, Guns With A Light Source, Armor, Camouflage, And Targets (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5335197P | 1997-07-22 | 1997-07-22 | |
| US5353597P | 1997-07-23 | 1997-07-23 | |
| GBGB9717590.5A GB9717590D0 (en) | 1997-08-20 | 1997-08-20 | Oral method for treating or preventing abnormal bone resorption |
| GBGB9717850.3A GB9717850D0 (en) | 1997-08-22 | 1997-08-22 | Oral method for treating or preventing abnormal bone resorption |
| PCT/US1998/014796 WO1999004773A2 (en) | 1997-07-22 | 1998-07-17 | Method for inhibiting bone resorption |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9810779A true BR9810779A (pt) | 2000-07-25 |
Family
ID=27451690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9810779-8A BR9810779A (pt) | 1997-07-22 | 1998-07-17 | Processos para inibir a reabsorção óssea em um mamìfero, para tratar e prevenir a osteoporose em um mamìfero, para tratar e prevenir a reabsorção óssea anormal em um ser humano, composição farmacêutica, e, conjunto para inibir a reabsorção óssea em um mamìfero |
Country Status (31)
| Country | Link |
|---|---|
| EP (5) | EP1175904B8 (enExample) |
| JP (2) | JP3479780B2 (enExample) |
| KR (3) | KR20030097611A (enExample) |
| CN (3) | CN1602879A (enExample) |
| AT (2) | ATE357921T1 (enExample) |
| AU (1) | AU8493698A (enExample) |
| BG (1) | BG66282B1 (enExample) |
| BR (1) | BR9810779A (enExample) |
| CA (1) | CA2294595C (enExample) |
| CY (2) | CY1107535T1 (enExample) |
| DE (6) | DE69803291T2 (enExample) |
| DK (2) | DK0998292T3 (enExample) |
| EA (1) | EA004544B2 (enExample) |
| EE (1) | EE05603B1 (enExample) |
| ES (3) | ES2253136T1 (enExample) |
| HK (4) | HK1042230A1 (enExample) |
| ID (1) | ID24096A (enExample) |
| IL (1) | IL133535A0 (enExample) |
| IS (3) | IS5315A (enExample) |
| LU (2) | LU91222I2 (enExample) |
| NL (2) | NL300223I1 (enExample) |
| NO (1) | NO20000323L (enExample) |
| NZ (1) | NZ501807A (enExample) |
| PL (1) | PL195272B1 (enExample) |
| PT (2) | PT998292E (enExample) |
| SG (2) | SG139556A1 (enExample) |
| SI (1) | SI0998292T1 (enExample) |
| SK (1) | SK932000A3 (enExample) |
| TR (1) | TR200000145T2 (enExample) |
| UY (1) | UY25950A1 (enExample) |
| WO (1) | WO1999004773A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3219402B2 (ja) | 1998-12-25 | 2001-10-15 | 山之内製薬株式会社 | 多発性骨髄腫の骨病変治療用医薬組成物 |
| EP1178810B8 (en) * | 1999-05-21 | 2005-07-27 | Novartis AG | Use of bisphosphonic acids for treating angiogenesis |
| EP1114642B1 (en) * | 1999-07-19 | 2010-01-06 | Toray Industries, Inc. | Drugs for periodontal diseases |
| WO2001046040A1 (en) | 1999-12-20 | 2001-06-28 | Merck & Co., Inc. | Blister package for pharmaceutical treatment card |
| WO2001045636A1 (en) * | 1999-12-20 | 2001-06-28 | Merck & Co., Inc. | Pharmaceutical kit |
| WO2001076577A2 (en) * | 2000-04-07 | 2001-10-18 | The Board Of Regents Of The University Of Texas System | Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity |
| DK1296689T3 (da) | 2000-06-20 | 2005-11-28 | Novartis Ag | Fremgangsmåde til indgivelse af bisphosphonater |
| EP1591122B1 (en) * | 2000-06-20 | 2012-09-26 | Novartis AG | Method of administering bisphosphonates |
| US6638920B2 (en) * | 2000-07-21 | 2003-10-28 | Merck & Co., Inc. | Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses |
| SE0101379D0 (sv) * | 2001-04-18 | 2001-04-18 | Diabact Ab | Komposition som hämmar utsöndring av magsyra |
| BR0209360A (pt) * | 2001-05-02 | 2004-06-08 | Novartis Ag | Método de administração de bisfosfonatos por inalação no tratamento ou prevenção de reabsorção óssea e osteoporose |
| BR0308901A (pt) * | 2002-05-10 | 2005-01-04 | Hoffmann La Roche | ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose |
| SE0203065D0 (sv) | 2002-10-16 | 2002-10-16 | Diabact Ab | Gastric acid secretion inhibiting composition |
| AU2004273672A1 (en) * | 2003-09-19 | 2005-03-31 | Wisconsin Alumni Research Foundation | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a bisphosphonate |
| WO2005072747A1 (ja) * | 2004-02-02 | 2005-08-11 | Ono Pharmaceutical Co., Ltd. | 骨吸収抑制剤 |
| NZ567200A (en) * | 2005-09-16 | 2010-08-27 | Selamine Ltd | Bisphosphonate formulation |
| US9592195B2 (en) * | 2010-12-06 | 2017-03-14 | Effrx Pharmaceuticals Sa | Stable effervescent bisphosphonate formulations with rapid solubilization characteristics |
| CN106924257B (zh) * | 2017-03-14 | 2019-11-19 | 湖南赛隆药业有限公司 | 质子泵抑制剂和抗骨质疏松药的复合物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL84731A0 (en) * | 1986-12-19 | 1988-05-31 | Norwich Eaton Pharma | Heterocycle-substituted diphosphonic acids and salts and esters and pharmaceutical compositions containing them |
| SE8704436D0 (sv) * | 1987-11-13 | 1987-11-13 | Pm Konsult Handelsbolag | Anvendning av antisekretoriska substanser for nya indikationer |
| ATE122228T1 (de) * | 1991-07-01 | 1995-05-15 | Gergely Gerhard | Verfahren zur herstellung einer pharmazeutischen zubereitung mit wenigstens zwei verschiedenen wirkstoffen und verwendung einer solchen zubereitung. |
| CZ282760B6 (cs) * | 1991-11-22 | 1997-09-17 | Procter And Gamble Pharmaceuticals, Inc. | Risedronátové prostředky se zpožděným uvolňováním |
| US5270365A (en) * | 1991-12-17 | 1993-12-14 | Merck & Co., Inc. | Prevention and treatment of periodontal disease with alendronate |
| US5294433A (en) * | 1992-04-15 | 1994-03-15 | The Procter & Gamble Company | Use of H-2 antagonists for treatment of gingivitis |
| ES2111163T3 (es) * | 1992-06-30 | 1998-03-01 | Procter & Gamble Pharma | Uso de fosfonatos para el tratamiento de la osteoporosis. |
| US5431920A (en) * | 1993-09-21 | 1995-07-11 | Merck Frosst, Canada, Inc. | Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents |
| US5646134A (en) * | 1994-04-21 | 1997-07-08 | Merck & Co., Inc. | Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices |
| EP0831843A1 (en) * | 1995-06-06 | 1998-04-01 | Merck & Co., Inc. | Bisphosphonate therapy for bone loss associated with rheumatoid arthritis |
| DE69726879T2 (de) * | 1996-05-17 | 2004-10-14 | Merck & Co., Inc. | Biphosphonat-formulierung mit brausewirkung |
-
1998
- 1998-07-17 DE DE69803291T patent/DE69803291T2/de not_active Revoked
- 1998-07-17 EP EP01201913A patent/EP1175904B8/en not_active Revoked
- 1998-07-17 KR KR1020027013595A patent/KR20030097611A/ko not_active Ceased
- 1998-07-17 WO PCT/US1998/014796 patent/WO1999004773A2/en not_active Ceased
- 1998-07-17 SK SK93-2000A patent/SK932000A3/sk not_active Application Discontinuation
- 1998-07-17 DE DE01201913T patent/DE01201913T1/de active Pending
- 1998-07-17 EA EA200000151A patent/EA004544B2/ru not_active IP Right Cessation
- 1998-07-17 ES ES01201910T patent/ES2253136T1/es active Pending
- 1998-07-17 EP EP98935752A patent/EP0998292B1/en not_active Revoked
- 1998-07-17 EE EEP200000040A patent/EE05603B1/xx unknown
- 1998-07-17 DE DE01201911T patent/DE01201911T1/de active Pending
- 1998-07-17 ID IDW20000114A patent/ID24096A/id unknown
- 1998-07-17 CN CNA2004100557346A patent/CN1602879A/zh active Pending
- 1998-07-17 PT PT98935752T patent/PT998292E/pt unknown
- 1998-07-17 PT PT01201913T patent/PT1175904E/pt unknown
- 1998-07-17 CN CNB2004100557350A patent/CN1299689C/zh not_active Expired - Lifetime
- 1998-07-17 EP EP01201912A patent/EP1175903A3/en not_active Ceased
- 1998-07-17 SG SG200603406-0A patent/SG139556A1/en unknown
- 1998-07-17 KR KR1020027013594A patent/KR20030097610A/ko not_active Ceased
- 1998-07-17 AT AT01201913T patent/ATE357921T1/de active
- 1998-07-17 CN CNB988074737A patent/CN1166365C/zh not_active Ceased
- 1998-07-17 BR BR9810779-8A patent/BR9810779A/pt not_active Application Discontinuation
- 1998-07-17 JP JP50991499A patent/JP3479780B2/ja not_active Expired - Lifetime
- 1998-07-17 CA CA002294595A patent/CA2294595C/en not_active Expired - Fee Related
- 1998-07-17 DE DE69837450T patent/DE69837450T2/de not_active Expired - Lifetime
- 1998-07-17 IL IL13353598A patent/IL133535A0/xx unknown
- 1998-07-17 SI SI9830086T patent/SI0998292T1/xx unknown
- 1998-07-17 DE DE1998603291 patent/DE122006000009I1/de active Pending
- 1998-07-17 TR TR2000/00145T patent/TR200000145T2/xx unknown
- 1998-07-17 ES ES01201913T patent/ES2269014T3/es not_active Expired - Lifetime
- 1998-07-17 EP EP01201911A patent/EP1151752A3/en not_active Ceased
- 1998-07-17 DE DE200712000063 patent/DE122007000063I1/de active Pending
- 1998-07-17 PL PL98338635A patent/PL195272B1/pl unknown
- 1998-07-17 DK DK98935752T patent/DK0998292T3/da active
- 1998-07-17 NZ NZ501807A patent/NZ501807A/en not_active IP Right Cessation
- 1998-07-17 DK DK01201913T patent/DK1175904T3/da active
- 1998-07-17 ES ES98935752T patent/ES2164447T3/es not_active Expired - Lifetime
- 1998-07-17 AU AU84936/98A patent/AU8493698A/en not_active Abandoned
- 1998-07-17 KR KR1020007000680A patent/KR100391732B1/ko not_active Expired - Fee Related
- 1998-07-17 AT AT98935752T patent/ATE209037T1/de active
- 1998-07-17 SG SG200107221A patent/SG109478A1/en unknown
- 1998-07-17 EP EP01201910A patent/EP1132088A3/en not_active Ceased
-
1999
- 1999-12-21 IS IS5315A patent/IS5315A/is unknown
-
2000
- 2000-01-17 UY UY25950A patent/UY25950A1/es not_active Application Discontinuation
- 2000-01-18 BG BG104093A patent/BG66282B1/bg unknown
- 2000-01-21 NO NO20000323A patent/NO20000323L/no unknown
-
2002
- 2002-03-04 HK HK02101656.1A patent/HK1042230A1/en unknown
- 2002-03-12 HK HK02101869.4A patent/HK1042232A1/en unknown
- 2002-03-16 HK HK02102042.2A patent/HK1040494A1/en unknown
- 2002-03-16 HK HK02102043.1A patent/HK1040495A1/en unknown
-
2003
- 2003-03-10 JP JP2003063378A patent/JP2005068010A/ja active Pending
-
2004
- 2004-04-21 IS IS7231A patent/IS7231A/is unknown
- 2004-04-21 IS IS7230A patent/IS7230A/is unknown
-
2006
- 2006-02-07 NL NL300223C patent/NL300223I1/nl unknown
- 2006-02-15 LU LU91222C patent/LU91222I2/fr unknown
-
2007
- 2007-03-29 CY CY20071100442T patent/CY1107535T1/el unknown
- 2007-09-12 LU LU91364C patent/LU91364I2/fr unknown
- 2007-09-13 NL NL300292C patent/NL300292I1/nl unknown
- 2007-09-20 CY CY2007022C patent/CY2007022I1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LU91364I2 (fr) | Alendronate de sodium /colécalciférol | |
| NZ545804A (en) | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-or-vitamin D derivatives and a bisphosphonate | |
| Fleisch | Bisphosphonates: mechanisms of action and clinical use in osteoporosis-an update | |
| NZ272608A (en) | Inhibiting bone loss by administering a bisphosphonate and a second compound selected from various compounds, including 2-phenyl-3-aroylbenzothienes; bisphosphonate combination salts | |
| CA2438848A1 (en) | Compositions for delivering bisphosphonates | |
| DE69528525D1 (de) | Feuchtgranulierung formulierung für bisphosphonsäuren | |
| JP2005530819A5 (enExample) | ||
| YU1800A (sh) | Upotreba bisfosfonata za proizvodnju leka za inhibiranje resorpcije kostiju | |
| Lazar et al. | Bisphosphonates in bone diseases treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: ALTERADA DE INT.CL.8: A61K 31/663, A61P 19/08, A61P 19/10 Ipc: A61K 31/663 (2007.01), A61P 19/08 (2007.01), A61P |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE A MATERIA DO PRESENTE PEDIDO NAO E PASSIVEL DE PROTECAO EM VISTA DO ARTIGO 10 ( VIII ) DA LEI 9279/96 |
|
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: MERCK SHARP AND DOHME CORP. (US) Free format text: NOME ALTERADO DE: MERCK AND CO., INC. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08H | Application fees: decision cancelled [chapter 8.8 patent gazette] |